Obesity

Novo Nordisk aims to launch more than five blockbuster drugs by 2030: CEO

The company is racing ​to reassure markets that ​it can navigate patent expirations for semaglutide - the active ingredient in its anti-obesity ​drugs Ozempic and Wegovy franchises, in the early 2030s

Novo Nordisk's Wegovy helped 40% of young children beat obesity: Study

The drug helped older kids lose weight in earlier studies but this marks the first trial looking at its effect on young children.

FSSAI proposes new limits for high-fat, sugar and salt foods in schools

The new framework aims to identify foods high in added fat, sugar and salt, while setting clearer nutritional benchmarks for food available to schoolchildren

Novo outlook hike falls flat as Wegovy pill sales fail to impress

Novo Nordisk raised its 2026 outlook, but investor sentiment remained subdued as Wegovy pill sales disappointed and CagriSema faced another setback

Improving Nutritional Outcomes: Ground-level lessons for India's nutrition

As India moves from food security to nutrition security, this book serves as a guide for policymakers, bridging the gap between theory and grassroots realities

Novo Nordisk's Wegovy gets CDSCO nod for fatty liver disease indication

The approval makes Wegovy the first GLP-1 therapy cleared in India for treating adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis

Explained: Why Nestle is tweaking flavours for people taking GLP-1 drugs

Nestle's chefs are working with people taking GLP-1 drugs to develop new flavour combinations, including potentially using more spices and pepper to compensate for dulled taste perception

Generic semaglutide market shows signs of excess inventory bulge

Distributors grapple with rising semaglutide inventory amid slower liquidation

India's GLP-1 market enters slower growth phase after semaglutide surge

After a near fourfold expansion driven by generic semaglutide launches, India's GLP-1 market is showing signs of moderation as patient onboarding growth slows

Next-gen obesity drug curbs sleep apnea, aids weight loss: Eli Lilly

In a Phase 3 trial, Lilly found a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6 per cent in adults with obesity

Eli Lilly and Novo Nordisk looking beyond US for obesity drug growth

Novo Nordisk and Eli Lilly are expanding obesity drug access globally as demand grows beyond the US and cheaper semaglutide generics enter new markets

Alkem launches semaglutide pre-filled syringes in India at ₹350

The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for diabetes and obesity

Worsening side effects of life in fast lane: Obesity, diabetes up sharply

Lifestyle diseases on the rise, shows NFHS-6, though insurance coverage, vaccination rates, maternal care, child health indicators have improved

France becomes first EU country to reimburse anti-obesity drugs: Minister

Patients in France are currently paying around €300 ​per month on average for the drugs, she said, without indicating how many people currently follow such treatments

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

CDSCO has directed states and UTs to curb surrogate advertising of GLP-1 obesity drugs amid rising sales and aggressive awareness campaigns

India joins weight-loss drug race, but affordability remains a concern

India is in the race for a new class of weight-loss drugs, but the question is: Will they be affordable?

How Chinese oral GLP-1 drugs may reshape India's obesity drug market

With cheaper GLP-1 pills entering India, access could improve significantly, but experts warn that affordability must be balanced with strong regulation and patient safety

GLP-1 sees strong return dosage in China and Japan as India lags on value

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Semaglutide generics hit Mounjaro sales, market share after patent expiry

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Emcure slashes obesity drug Poviztra price by up to 55% amid competition

Emcure cuts Poviztra prices by up to 55% following Novo Nordisk's move, lowering monthly treatment costs for semaglutide-based obesity therapy in India